Etienne Brain, MD, PhD, on Breast Cancer: Adjuvant Endocrine Therapy With or Without Chemotherapy in Older Patients

2022 ASCO Annual Meeting


Etienne Brain, MD, PhD, of the Institut Curie, discusses phase III findings from the Unicancer ASTER 70s trial, in which patients aged 70 or older with estrogen receptor–positive, HER2-negative breast cancer and a high genomic grade index received adjuvant endocrine therapy with or without chemotherapy. The data did not find a statistically significant overall survival benefit with this treatment after surgery (Abstract 500).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
ASTER 70s study is a landmark study, which has been conducted in older women with luminal breast cancer in adjuvant setting questioning the addition of chemotherapy to endocrine treatment. The rationale behind is that the literature is very limited in terms of data published for the use of adjuvant chemotherapy in this situation in older ones. Multimorbidity competes with cancer on outcome and therapeutic ratio is also more narrow because there are higher risk of side effects in this population. This trial screened near 2000 patients with the genomic grade index, the GGI, to assess the aggressivity of the disease and to spare the burden of chemotherapy in those patients with low-GGI tumor, while those with a high-GGI tumor were randomized between endocrine treatment alone as a standard arm versus chemotherapy followed by endocrine treatment. Near 2000 patients enrolled, 1,100 randomized between the two arms. This trial shows, on the primary endpoint, which was overall survival by intent-to-treat analysis, that chemotherapy doesn't add a significant benefit in addition to endocrine treatment. That's the first message of caution from this study. Second one is that we can look at different subgroups and perform also the analysis according to the per protocol concept. This modifies or brings a nuance in the results, but I would say that the final potential benefit on overall survival in this case remains marginal. And in this population of older women, it is a key point and a double cautious message. The next step for this study will be to try to improve the discriminative capacity of this kind of signature to identify those who could benefit still from chemotherapy, despite these global message and results on overall survival. This will be certainly possible with the use of the mass and the volume of data which has been collected in the randomized groups in this study, because there was a longitudinal collection of geriatric data, quality of life data, and treatment acceptability socioeconomic data, which will be very helpful to modelize differently, the prognosis of these ladies. That's in the near future, and I think what brings the most in terms of information ASTER 70s, is that on the provisor that you change a bit of rules for inclusion criteria, because in this study we had very flexible inclusion criteria, we made a focus on quality of life and we use a single informed consent for screening and randomization, on the provisor that you facilitate or you simplify the processes, you can run large studies in a vast population, which is very often not considered for clinical trials left behind.

Related Videos

Supportive Care

Manali I. Patel, MD, MPH, on Equitable, Value-Based Care: The Effectiveness of Community Health Worker–Led Interventions

Manali I. Patel, MD, MPH, of Stanford University School of Medicine, discusses clinical trial findings on the best ways to integrate community-based interventions into cancer care delivery for low-income and minority populations. Such interventions may improve quality of life and patient activation (often defined as patients having the knowledge, skills, and confidence to manage their health), as well as reduce hospitalizations and the total costs of care (Abstract 6500).

Issues in Oncology
Global Cancer Care

Clifford A. Hudis, MD, and Karen E. Knudsen, PhD, MBA, on How ASCO and the American Cancer Society Are Collaborating to Help Patients With Cancer

Clifford A. Hudis, MD, of the American Society of Clinical Oncology, and Karen E. Knudsen, PhD, MBA, of the American Cancer Society, discuss their collaboration, pooling their research and education resources to help empower patients with cancer and their families. Within 48 hours, Drs. Hudis and Knudsen were able to gear up a rapid response to the crisis in Ukraine, forming a clinical corps of volunteers to post information online in multiple languages, which helped patients navigate their care in the war-torn region. To date, 300 European cancer organizations have joined their efforts.

Head and Neck Cancer

Sue S. Yom, MD, PhD, on Oropharyngeal Cancer and the Feasibility of a Cell-Free DNA Plasma Assay

Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses a translational analysis from the NRG-HN002 study. This phase II trial established the feasibility of the tumor tissue–modified viral (TTMV) human papillomavirus DNA assay in clinical trial specimens. The goal is to use such an assay to measure tumor volume, levels of TTMV over the course of treatment, and the association of TTMV to treatment outcomes (Abstract 6006).


Prostate Cancer

Alicia K. Morgans, MD, MPH, and Ian D. Davis, PhD, MBBS, on Prostate Cancer: Updated Overall Survival Outcomes With Enzalutamide

Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Ian D. Davis, PhD, MBBS, of Monash University and Eastern Health, discuss the latest findings from ANZUP Cancer Trials Group’s ENZAMET cooperative group trial of enzalutamide in patients with metastatic hormone-sensitive prostate cancer. The results corroborate the benefit of enzalutamide with improved overall survival, and involve some exploratory subgroup analyses (Abstract LBA5004).

Pancreatic Cancer

Pamela L. Kunz, MD, on Pancreatic Neuroendocrine Tumors: A Final Analysis of Temozolomide or Temozolomide Plus Capecitabine

Pamela L. Kunz, MD, of the Yale University School of Medicine, discusses new findings from the ECOG-ACRIN E2211 trial, which showed the longest progression-free survival and highest response rates with temozolomide plus capecitabine reported to date for patients with pancreatic neuroendocrine tumors. The presence of a deficiency of MGMT, the drug-resistance gene, was associated with greater odds of an objective response (Abstract 4004).